| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.17 | 0.0001 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0002 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.2 | 0.0002 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |